Enhancing in situ cancer vaccines using delivery technologies
Related Experiment Video
Updated: Jun 22, 2025
Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
Ningqiang Gong1,2, Mohamad-Gabriel Alameh3,4,5, Rakan El-Mayta3
1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
In situ cancer vaccination refers to any approach that exploits tumour antigens available at a tumour site to induce tumour-specific adaptive immune responses. These approaches hold great promise for the treatment of many solid tumours, with numerous candidate drugs under preclinical or clinical evaluation and several products already approved. However, there are challenges in the development of effective in situ cancer vaccines. For example, inadequate release of tumour antigens from tumour cells limits antigen uptake by immune cells; insufficient antigen processing by antigen-presenting cells restricts the generation of antigen-specific T cell responses; and the suppressive immune microenvironment of the tumour leads to exhaustion and death of effector cells. Rationally designed delivery technologies such as lipid nanoparticles, hydrogels, scaffolds and polymeric nanoparticles are uniquely suited to overcome these challenges through the targeted delivery of therapeutics to tumour cells, immune cells or the extracellular matrix. Here, we discuss delivery technologies that have the potential to reduce various clinical barriers for in situ cancer vaccines. We also provide our perspective on this emerging field that lies at the interface of cancer vaccine biology and delivery technologies.
Insights
In situ cancer vaccination uses tumor antigens to create immune responses against cancer. Delivery technologies are crucial for overcoming challenges like poor antigen release and suppressive tumor microenvironments, improving vaccine effectiveness.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- In situ cancer vaccination aims to induce tumor-specific immune responses using local tumor antigens.
- Despite promise and approved products, challenges hinder effectiveness, including antigen release, processing, and the immunosuppressive tumor microenvironment.
- Delivery technologies offer solutions to overcome these clinical barriers.
Purpose of the Study:
- To review delivery technologies for in situ cancer vaccines.
- To discuss how these technologies address clinical barriers in cancer vaccine development.
- To provide a perspective on the intersection of cancer vaccine biology and delivery systems.
Main Methods:
- Discussion of various delivery technologies (lipid nanoparticles, hydrogels, scaffolds, polymeric nanoparticles).
- Analysis of how these technologies target tumor cells, immune cells, or the extracellular matrix.
- Review of current literature and clinical evaluations of in situ cancer vaccines and delivery systems.
Main Results:
- Delivery technologies can enhance antigen availability and uptake by immune cells.
- Targeted delivery can improve antigen processing by antigen-presenting cells.
- Advanced delivery systems can mitigate the suppressive tumor microenvironment, reducing effector cell exhaustion.
Conclusions:
- Delivery technologies are essential for overcoming critical barriers in in situ cancer vaccination.
- Rational design of delivery systems holds significant potential for advancing cancer vaccine therapy.
- This field merges cancer vaccine biology with cutting-edge delivery technologies for improved therapeutic outcomes.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
00:59Gene Therapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...